BioPharma Dive4d
Flagship startup raises $200M in pursuit of ‘scientific superintelligence’
Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...
BioPharma Dive3d
Mallinckrodt, Endo to combine in $7B deal
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...
BioPharma Dive4d
Ono pays $280M to license Ionis rare disease drug
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
BioPharma Dive2d
Advancing siRNA Drug Discovery and Development with AI
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
BioPharma Dive10d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
BioPharma Dive5d
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
BioPharma Dive5d
Douglas Kelly, deputy science director at FDA’s device center, leaves agency
Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...
BioPharma Dive6d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
BioPharma Dive2d
FDA sets flu shot recommendations without input of outside advisers
The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...
BioPharma Dive10d
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
BioPharma Dive2d
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...
BioPharma Dive5d
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...